USE OF CD47 ANTIBODIES

• US 20190330341A1
• Filed: 01/09/2018
• Published: 10/31/2019
• Est. Priority Date: 01/10/2017
• Status: Abandoned Application

• Current Assignee: Matthias Totzeck, Tienush Rassaf
• Original Assignee: Matthias Totzeck, Tienush Rassaf
• Inventors: TOTZECK, Matthias, RASSAF, Tienush
• Application Number:
  US16/476,743
• Publication Number:
  US 20190330341A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to CD47 antibodies or fragments thereof binding specifically to the CD47 immunogen for use in preventing or treating tissue injury in states of ischemia or reperfusion in an object whereby the CD47 antibodies or fragments thereof are introduced intravascularly at the or near by the place of ischemia or reperfusion.

Claims

1-14. -14. (canceled)

15. A method for preventing or treating tissue injury in states of ischemia and reperfusion in a subject comprising the step of administering CD47 antibodies or fragments thereof binding specifically to the CD47 immunogen, whereby the CD47 antibodies or fragments thereof are introduced intravascularly.

16. The method for preventing or treating tissue injury in states of ischemia and reperfusion in a subject according to claim 15 wherein administration is intravascularly at the place ischemia or reperfusion.

17. The method according to claim 16 wherein administration is into the coronary artery.

18. The method according to claim 15 Wherein the subject is a human and the CD47 immunogen is the immunogen having the sequence of SEQ ID No. 2 and the CD47 antibodies or fragments thereof are humanized antibodies or fragments thereof.

19. The method according to claim 15 wherein the administration by intravascular introduction is by catheter, by infusion and/or other intravenous administration, by intraventricular administration or combinations thereof.

20. The method according to claim 15 wherein the ischemia and reperfusion is a result of

i) myocardial infarction,

ii) cardiac arrest and resuscitation,

iii) coronary bypass surgery under the use of an extracorporal life support systems,

iv) treatment of chronic coronary total occlusion lesions,

v) treatment of type B aortic dissection using catheter interventional techniques,

vi) stroke and interventional stroke treatment,

vii) cardiogenic shock,

viii) heart transplantation,

ix) replacement of aortic valves or

x) high risk coronary interventions under the use of circulatory support systems.

21. The method according to claim 15 wherein administration is performed regionally at the or near by the place of ischemia or reperfusion within the first 30 minutes after ischemia or reperfusion.

22. The method according to claim 21 wherein administration is performed regionally within the first 15 minutes after ischemia or reperfusion.

23. The method according to claim 21 wherein administration is followed by continuous infusion of the CD47 antibodies or fragments thereof binding specifically to the CD47 immunogen.

24. The method according to claim 15 wherein administration is by continuous infusion.

25. The method according to claim 15 wherein the treatment is a prophylactic treatment before heart transplantation or replacement of vessels.

26. The method according to claim 25 wherein the replacement of vessels is replacement of artery and veins including aorta.

27. The method according to claim 15 wherein the subject is a subject undergoing treatment.

28. The method according to claim 27 wherein said subject is a subject undergoing surgery including extracorporal support systems.

29. The method according to claim 15 wherein the administration by intravascular introduction is in concert with an infusion of the said CD47 antibodies or fragments thereof.

30. The method according to claim 29 wherein the administration by intravascular introduction is at the place of ischemia or reperfusion.

31. The method according to claim 29 wherein the administration by intravascular introduction is simultaneously or sequentially with the infusion of said CD47 antibodies or fragments thereof.

32. The method according to claim 31 wherein the administration by intravascular introduction is at the place of ischemia or reperfusion.

33. The method according to claim 15 wherein the CD47 antibodies or fragments thereof are administered intravascularly by catheter for inhibiting locally CD47 signaling for removing damaged cells by phagocytic machinery for improving reperfusion injury.

34. The method according to claim 33 wherein the administration is at the place of ischemia or reperfusion.

35. The method according to claim 34 wherein the administration is by catheter in a damaged organ.

36. The method according to claim 15 wherein the administration is by a combination of a first administration of an initiate dosage in form of intraventricular injection of a bolus or intravenous injection of a bolus or by catheter to the coronary artery followed by continuous infusion.

37. The method according to claim 15 wherein the CD47 antibodies are an isolated chimeric or humanized antibody that specifically bind to human CD47, wherein said antibody comprises a heavy chain having each of the CDR sequences set forth in SEQ ID Nos. 3, 4, 5, or each of the CDR sequences set forth in SEQ ID Nos. 6, 7, 8, or each of the CDR sequences set forth in SEQ ID Nos. 9, 10, 11 and a light chain having each of the CDR sequences set forth in SEQ ID No. 12, 13, 14, or each of the CDR sequences set forth in SEQ ID Nos. 15, 16, 17, or each of the CDR sequences set forth in SEQ ID Nos. 18, 19, 20.

38. The method according to claim 15 wherein the CD47 antibodies or fragments thereof are a monoclonal antibody or antigen binding fragment thereof which comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR and said HCVR comprise, respectively, amino acid sequences selected from among the following combinations of one of the LCVRs of SEQ ID Nos. 21 to 45 and one of the HCVRs of SEC, ID Nos. 47 to 71,

wherein each one of the LCVR SEQ ID Nos 21 to 45 further comprises a constant domain having the amino acid sequence shown in SEQ ID No 46, and

wherein each one of the HCVR SEQ ID Nos 47 to 71 comprises a constant domain selected from among SEQ ID Nos 72, 73, 74, 75, 76.

39. The method according to claim 38 wherein the antibody or antigen binding fragment thereof comprises three light chain complementary determining regions (LCDRs 1-3) and three heavy chain complementary determining regions (HCDRs 1-3), wherein:

LCDR 1 comprises the amino add sequence RSSQSLVHSNGNTYLH (SEQ ID NO;

77)

LCDR 2 comprises the amino acid sequence KVSYRFS (SEQ ID NO;

78);

LCDR 3 comprises the amino acid sequence SQNTHVPRT (SEQ ID NO;

79);

HCDR 1 comprises the amino acid sequence GYTFTNYYVF (SEQ ID NO;

80);

HCDR 2 comprises the amino acid sequence DINPVNGDTNFNEKFKN (SEQ ID NO;

81); and

HCDR 3 comprises the amino acid sequence GGYTMDY (SEQ ID NO;

82).